Cystic Fibrosis (CF)
Conditions
Interventions
None listed
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
2 Years to 11 Years
Inclusion criteria
Inclusion criteria: Children with CF: - Age 0-4 years; (0 years up to and including 4 years) - Diagnosis of CF confirmed by sweat-test and/or DNA analysis and/or electro physiology testing (nasal potential difference measurement or intestinal current measurement); - Clinically stable patients: no hospital admission and no need for an antibiotic course for at least 4 weeks prior to enrolment in the study; - No signs of (viral) respiratory infection in the period from 1 week (7 days) before the measurement until the day of the measurement. (Viral) respiratory infection is defined as a combination of the following symptoms: rhinitis; pharyngitis; cough; headache; fever; - Signed written informed consent.;Healthy controls: - Age 0-4 years; - No use of an antibiotic course (for pulmonary reasons) for at least 4 weeks prior to enrolment in the study; - No signs of respiratory infection in the period from 1 week (7 days) before the measurement until the day of the measurement (definition of viral infection see children with CF); - Signed written informed consent.
Exclusion criteria
Exclusion criteria: All study participants: - Medical conditions that might affect the measurements (e.g. cardiac problems that can influence saturation, BPD (bronchopulmonary dysplasia)) that can influence LCI, etc.).;Children with CF: - Pulmonary exacerbation at the time of the study.;Healthy controls: - History of pulmonary diseases such as asthma, BPD, airway malacia; - Current use of pulmonary drugs; - History of premature birth (before 37 weeks gestation); - ENT related interventions in recent history (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Gas mixing measured by the Exhalyzer®D. - Nightly oxygen saturation measured by the Novametrix Model 2001 MARS pulse oximeter. - Nightly cough measured with an audio meter. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Differences between healthy children and children with CF. - Feasability (% successfully performed measurements) of the measurements. | — |
Countries
Netherlands
Outcome results
None listed